Is Qualigen Therapeutics a buy or sell stock?

The Qualigen Therapeutics Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal .

What is the price forecast for Qlgn?

According to our Ritter Pharmaceuticals stock prediction for 2025, QLGN stock will be priced at $ 0.424672 in 2025 . This forecast is based on the stock's average growth over the past 10 years.

Who is the CEO of Qualigen Therapeutics?

Chairman/Chief Executive Officer/Founder, Qualigen Therapeutics Inc.

What is the future price of MDT stock?

MDT Stock 12 Month Forecast Based on 15 Wall Street analysts offering 12 month price targets for Medtronic in the last 3 months. The average price target is $95.00 with a high forecast of $110.00 and a low forecast of $76.00 .

What is the meta stock price forecast for 2024?

Analytical Meta stock predictions in 2024 range between $540 and $642 by the end of the year. As of now, the stock is valued at around $495. Analysts are generally optimistic about Meta's growth prospects, driven by advancements in AI technology, the metaverse, and strong advertising revenue.

What is the meta stock price forecast for 2025?

Meta stock prediction for 1 year from now: $ 183.47 (-63.61%) Meta stock forecast for 2025: $ 674.63 (30.93%) Meta stock prediction for 2030: $ 2,595.63 (403.75%)

What is the stock price forecast for Eli Lilly in 2025?

Long-Term Lilly(Eli) & Co Stock Price Predictions Year Prediction Change 2025 $ 1,156.53 26.81% 2026 $ 1,466.64 60.82% 2027 $ 1,859.91 103.94% 2028 $ 2,358.63 158.62% 2 more rows

Qualigen Therapeutics Inc Stock Price and Quote (2024)

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.53	Insider Own	11.52%	Shs Outstand	6.79M	Perf Week	9.44%
Market Cap	2.00M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.01M	Perf Month	-7.25%
Income	-12.81M	PEG	-	EPS next Q	-	Inst Own	3.72%	Short Float	0.72%	Perf Quarter	-41.81%
Sales	3.23M	P/S	0.62	EPS this Y	-	Inst Trans	1.39%	Short Ratio	0.52	Perf Half Y	-59.60%
Book/sh	-0.39	P/B	-	EPS next Y	-	ROA	-122.88%	Short Interest	0.04M	Perf Year	-69.54%
Cash/sh	0.06	P/C	5.01	EPS next 5Y	-	ROE	-505.62%	52W Range	0.26 - 1.26	Perf YTD	-46.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	71.09%	ROI	-	52W High	-76.59%	Beta	-0.65
Dividend TTM	-	Quick Ratio	0.28	Sales past 5Y	-50.00%	Gross Margin	29.32%	52W Low	13.44%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	0.28	EPS Y/Y TTM	47.67%	Oper. Margin	-380.19%	RSI (14)	44.57	Volatility	10.77% 10.12%
Employees	4	Debt/Eq	-	Sales Y/Y TTM	-35.10%	Profit Margin	-396.23%	Recom	1.00	Target Price	33.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	69.23%	Payout	-	Rel Volume	0.81	Prev Close	0.29
Sales Surprise	-2.28%	EPS Surprise	3.39%	Sales Q/Q	-100.00%	Earnings	-	Avg Volume	82.56K	Price	0.29
SMA20	0.38%	SMA50	-13.65%	SMA200	-54.44%	Trades		Volume	67,063	Change	0.67%

open in yahoo|&nbspopen in reuters|&nbspopen in marketwatch|&nbspopen in google|&nbspopen in EDGAR

Qualigen Therapeutics Inc Stock Price and Quote (1)

Qualigen Therapeutics Inc Stock Price and Quote (2)

Apr-16-24 07:00AM	Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft (GlobeNewswire) -6.28%
Apr-10-24 08:00AM	Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-09-24 08:00AM	Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Nov-14-23 04:30PM	Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 (GlobeNewswire)
Nov-07-23 08:30AM	Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
08:30AM	Loading…
Oct-23-23 08:30AM	Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer (GlobeNewswire)
Sep-27-23 08:30AM	Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 (GlobeNewswire)
Aug-30-23 07:09AM	QLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23 (Zacks)
Aug-17-23 08:30AM	Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Aug-15-23 08:30AM	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 (GlobeNewswire)
Aug-01-23 08:30AM	Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Jul-24-23 08:15AM	Qualigen Therapeutics Divests FastPack® Diagnostics Business (GlobeNewswire)
Jun-14-23 10:30AM	QLGN: Data for Pan-RAS Platform Presented at ASCO (Zacks Small Cap Research)
Jun-05-23 08:15AM	Poster Highlighting Qualigen Therapeutics Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire)
May-16-23 08:00AM	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023 (GlobeNewswire)
07:20AM	Loading…
May-12-23 07:20AM	QLGN: IND for QN-302 to be Submitted in Mid-2023 (Zacks Small Cap Research) -5.69%
May-02-23 04:30PM	Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +7.29%
08:15AM	Qualigen Therapeutics Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire)
Apr-21-23 05:46PM	Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing (GlobeNewswire)
Apr-18-23 08:45AM	Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL (GlobeNewswire) -5.48%
07:30AM	Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL (GlobeNewswire)
Mar-21-23 08:35AM	Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office (GlobeNewswire) +16.33%
Mar-15-23 09:05AM	Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-09-23 08:30AM	Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference (GlobeNewswire)
Mar-08-23 08:05AM	Data on Potential Biomarker for Qualigen Therapeutics Lead Program QN-302 Published in Peer-Reviewed Journal Molecules (GlobeNewswire) -7.14%
Feb-01-23 09:05AM	Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders (GlobeNewswire) +10.85%
Jan-24-23 09:00AM	Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302 (GlobeNewswire)
Jan-23-23 09:02AM	Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications (GlobeNewswire)
Jan-10-23 09:00AM	Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer (GlobeNewswire) +5.51%
Jan-05-23 09:00AM	Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform (GlobeNewswire) +9.73%
08:30AM	Loading…
Dec-12-22 08:30AM	Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
Dec-07-22 09:10AM	Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors (GlobeNewswire) -6.21%
Dec-01-22 07:11AM	QLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor (Zacks Small Cap Research) +20.20%
Nov-22-22 09:00AM	Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -14.50%
Nov-17-22 06:12AM	Qualigen Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-15-22 07:30AM	Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-19-22 09:00AM	Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute (GlobeNewswire)
Oct-18-22 09:00AM	Qualigen Therapeutics to Present at LD Micro Main Event XV (GlobeNewswire)
Oct-06-22 08:00AM	Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium (GlobeNewswire) -10.06%
Sep-14-22 05:02PM	Qualigen Therapeutics Presents Data on QN-302 at AACRs Pancreatic Cancer Meeting (GlobeNewswire) -5.71%
Aug-25-22 06:45AM	QLGN: FastPack Sales Up 28% YoY (Zacks Small Cap Research)
Aug-18-22 09:15AM	Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board (GlobeNewswire)
Aug-16-22 07:30AM	Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-22 08:30AM	Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model (GlobeNewswire)
Jul-06-22 09:00AM	Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302 (GlobeNewswire)
Jun-14-22 09:00AM	Qualigen Therapeutics to Present at BIO International Convention (GlobeNewswire)
Jun-07-22 09:04AM	Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials (GlobeNewswire)
Jun-06-22 06:10AM	QLGN: Acquires Majority Stake in Israeli Diagnostics Technology Company NanoSynex (Zacks Small Cap Research)
Jun-02-22 09:00AM	Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex (GlobeNewswire) +5.36%
May-26-22 09:15AM	Qualigen Therapeutics Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting (GlobeNewswire)
May-20-22 09:15AM	Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 06:00AM	Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) +7.65%
May-10-22 09:17AM	Qualigen Therapeutics Partner NanoSynex to Present Technology at BioMed Israel (GlobeNewswire)
May-03-22 02:24PM	Qualigen Takes Stake In NanoSynex To Gain Access To Next-Gen Diagnostic Platform (Benzinga)
09:17AM	Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex (GlobeNewswire)
Apr-29-22 09:15AM	Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President (GlobeNewswire)
Apr-18-22 06:25AM	QLGN: Secures Worldwide Rights to G4-Selective Cancer Therapeutics (Zacks Small Cap Research) -12.75%
Apr-12-22 10:15AM	Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference (GlobeNewswire) +52.06%
Apr-05-22 09:15AM	Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack® (GlobeNewswire)
Apr-01-22 08:00AM	Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results (GlobeNewswire)
Mar-30-22 09:15AM	Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302 (GlobeNewswire)
Mar-22-22 09:15AM	Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference (GlobeNewswire) +8.04%
Mar-15-22 09:15AM	Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program (GlobeNewswire)
Feb-22-22 09:15AM	Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders (GlobeNewswire)
Feb-15-22 09:15AM	Data from Qualigen Therapeutics Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference (GlobeNewswire)
Feb-01-22 09:15AM	Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302 (GlobeNewswire)
Jan-18-22 09:15AM	Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics (GlobeNewswire)
Dec-14-21 09:18AM	Qualigen Therapeutics Promotes Amy Broidrick to President (GlobeNewswire)
Dec-01-21 03:25PM	Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering (GlobeNewswire)
Nov-29-21 03:50PM	QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING (GlobeNewswire) -7.06%
Nov-22-21 10:23AM	QLGN: Revenues Increase 38% YoY (Zacks Small Cap Research) +25.62%
07:43AM	Here's Why Qualigen Therapeutics (NASDAQ:QLGN) Must Use Its Cash Wisely (Simply Wall St.)
Nov-15-21 09:00AM	Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-19-21 09:00AM	Peer-Reviewed Article Confirms That Qualigens FastPack® is as Accurate in Thyroid Stimulating Hormone Measurement -- and Much Faster -- Than a Leading Laboratory Method (GlobeNewswire)
Sep-15-21 07:30AM	Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire) +5.11%
Sep-08-21 07:30AM	Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-31-21 06:22AM	QLGN: Focusing on Advancement of QN-247 and RAS-F (Zacks Small Cap Research) +22.66%
Aug-23-21 09:58AM	4 Penny Stocks Insiders Are Buying (Benzinga) +7.63%
Aug-17-21 10:01AM	Why Qualigen Therapeutics (QLGN) Stock Plunging After Q2 Update (Benzinga) -22.16%
08:00AM	Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results (GlobeNewswire)
07:02AM	25 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
Jul-14-21 07:30AM	Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19 (GlobeNewswire)
Jul-07-21 10:37AM	QLGN: On Track to File IND for QN-165 as COVID-19 Treatment in 2H21 (Zacks Small Cap Research) +7.85%
Jun-08-21 07:30AM	Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index (GlobeNewswire)
Jun-02-21 07:30AM	Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference (GlobeNewswire)
May-19-21 07:30AM	Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer (GlobeNewswire)
May-18-21 02:10PM	Qualigen Therapeutics Inc to Host Earnings Call (ACCESSWIRE)
May-14-21 01:35PM	Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-21 07:00AM	QLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2Q21 (Zacks Small Cap Research) +11.44%
07:00AM	QLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2H21 (Zacks Small Cap Research)
Apr-19-21 01:16PM	Qualigen Therapeutics Plans to Combat COVID-19 Variants (Benzinga)
Apr-06-21 09:30AM	Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-18-21 08:30AM	Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference (GlobeNewswire)
Mar-09-21 08:30AM	Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position (GlobeNewswire)
Mar-08-21 08:30AM	Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire) +10.07%
Mar-01-21 08:30AM	Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL (GlobeNewswire)
Jan-26-21 09:00AM	Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China (PR Newswire)
Dec-30-20 11:16AM	Insider Buys Qualigen Therapeutics Stock (Benzinga)
Dec-22-20 09:00AM	Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook (PR Newswire)
Dec-18-20 03:07PM	Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering (PR Newswire)

Qualigen Therapeutics Inc Stock Price and Quote (3)

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

Qualigen Therapeutics Inc Stock Price and Quote (4)

Qualigen Therapeutics Inc Stock Price and Quote (5)

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions withourpremium features. Real-time quotes, advancedvisualizations, backtesting, and much more.

Learn more about FINVIZ*Elite

Qualigen Therapeutics Inc Stock Price and Quote (2024)

Upgrade your FINVIZ experience

FAQs

Is Qualigen Therapeutics a buy or sell stock? ›

Year	Prediction	Change
2025	$ 1,156.53	26.81%
2026	$ 1,466.64	60.82%
2027	$ 1,859.91	103.94%
2028	$ 2,358.63	158.62%